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Abstract. The growing use of antineoplastic drugs in cancer therapy is an emerging issue in 
environmental research. The presence of the anticancer drug cyclophosphamide (CP) in 
municipal wastewater raises several environmental problems. Besides its cytotoxic effects, CP 
possesses teratogenic and mutagenic properties and is a known human carcinogen. The 
application of membrane bioreactor (MBR) technology was investigated with the aim of 
evaluating its potential for cytostatic drug bioremoval. The toxicity removal was assessed from 
biomarkers tests and related to the choice of the reactor operating conditions. The influence of 
sludge retention times (SRT) on CP removal was suited but not significant effects were found 
for variation of  SRT from 50 days to 70 days. CP removal up to 80% was achieved under 
studied operating conditions. In front of such pollution, evidence has been made about the use 
of MBR. Our study proofed that advances wastewater treatment using a MBR provides a 
suitable process for lowering CP concentrations before discharge into the aqueous environment. 
However, a tertiary treatment is necessary for the complete elimination of toxicity. 
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INTRODUCTION 
  
 Pharmaceuticals are designed to exhibit biological activity in humans and may basically have 
adverse effects on aquatic organisms. Pharmaceuticals and other micropolluants in wastewater pose a new 
challenge to wastewater professionals as well as to the pharmaceutical industry [1]. Compounds with a 
very potent mechanism of action such as cytostatic drugs are of particular environmental concern, even 
though consumption rates and expected concentrations in the environment may be comparatively low [2, 
3]. 
 
 The increase of the demand for chemotherapy treatment in developed countries goes on at around 
10% more per year. Further, cancer incidence is increasing and this is not simply due to a greater 
proportion of elderly people in the population [4]. The alkylating antineoplastic drug Cyclophosphamide 
(CP) is one of the oldest known cytostatics and is one of the most frequently used agents in cancer 
chemotherapy [5]. After application to patients the agent is renally excreted, whereby up to 20% of the 
dose may leave the body unmetabolized. Besides its cytotoxic effects, CP possesses teratogenic and 
mutagenic properties and is a known human carcinogen [6]. CP is a prodrug that requires 
biotransformation to become cytotoxic [7, 8]. It is transformed via hepatic and intracellular enzymes to 
active alkylating metabolites, 4-hydroxycyclophophosphamide, aldophosphamide, acrolein and 
phosphoramide mustard [9].  
 
 CP could be detected in concentrations ranging from 20ng/L to 4.5 µg/L in hospital sewage [6]. 
The occurrence of the agent could also be proved in samples from the influent and the effluent of the 
communal sewage treatment plant into which the hospital’s sewage water is discharged. Concentrations 
ranged from 7 to 143 ng/L [6]. CP has been detected in surface waters in Switzerland, concentrations 
ranged from 50 to 170 pg/L and were thus several orders of magnitude lower than the levels at which 
acute ecotoxicological effects have been reported in the literature (mg/L range). However, due to a lack of 
studies on chronic effects on aquatic organisms and data on occurrence and effects of metabolites, a final 
risk assessment cannot be made [3].    
 
 Membrane bioreactors (MBR) constitute a promising technology in industrial and urban 
wastewater treatment. The MBR incorporates a membrane for liquid-solid separation. Theoretically, 
several operational conditions exist in MBRs, which are in favour of enhanced biotransformation and 
mineralization of micropollutants [10, 11]. 
 
 The application of membrane bioreactor (MBR) technology is investigated here with the aim of 
evaluating its potential for cytostatic drug bioremoval. Toxicity and CP removal in a MBR were 
investigated.   
 
MATERIAL AND METHODS 
 
 The schematic diagram of crossflow MBR pilot system is shown in fig 1. The membrane modules 
were ceramic tubular Membralox® (MF) with 0.0055 m2 of surface area and pore size 0.2 µm (Pall 
Exekia, France). In order to keep a complete mixing in the bioreactor a Ruston turbine was installed. 
Dissolved oxygen and pH in the bioreactor were monitored.  The lab-scale crossflow MBR was used in 
the continous experiments. Cyclophosphamide (5µg/L) and its principal metabolites (Acrolein 2250 ng/l, 
Phosphoramide Mustard 8880 ng/L, 4-
ketocyclophosphamide (Keto CP) 580 
ng/L, Nitrogen Mustard 517 ng/L) 
were continuously added to the pilot. 
The MBR pilot was inoculated with 
activated sludge from a municipal 
sewage treatment plant (dry weight, 
3g/L).  Raw water was composed of 
domestic water and completed with 
Viandox® so as to reach the required 
Chemical oxygen demand (COD) 
amount. Treatment was operated in 
aerobic/anoxic conditions. The 
operating conditions of the MBR 
during the experimentation are given in 
Table 1. Two campaigns were run to 
investigate the sludge retention time, 
respectively campaign I for 50 days, 
campaign II for 70 days. 
 
Table 1. Operating conditions of the membrane bioreactor (MBR) during the experimentation 
 
Parameter experimental 
campaign I 
experimental campaign 
II 
working volume (L) 20 20 
Temperature (°C) 25-32 25-32 
pH 7-8 7-8 
flux (at 20°C, L.m-2h-1) 55.47 ± 8.37 83.87 ± 6.01 
Inlet COD (mg DCO/L) 2609 ± 512 1774.7 ± 629.6 
Organic loading rate (Kg COD.m-3.d-1) 1.02 ± 0.12 1.26 ± 0.42 
F/M (Kg CODinlet/KgMLSS/d) at steady-state. 0.11 0.11 
Solids retention time (SRT) (d) 50 70 
Hydraulic retention time (HRT) (h) 48 32 
aeration cycle 2 minutes aeration/23 
without aeration 
2 minutes aeration/17 
without aeration 
Crossflow velocity (m/s) 4-5 4-5 
 
The chemical composition of soluble extracellular polymeric substances (EPS), was analyzed for proteins, 
humic substances and polysaccharides. Proteins and humic substances were measured by the modified 
Lowry method with Bovine serum Albumin and humic acid as standard [12]. Polysaccharides were 
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Fig. 1 Schematic diagram of MBR pilot 
pilot. 
determined according to the anthrone method with glucose as standard [13]. The transmembrane pressure 
(TMP) which indicates the extent of membrane fouling was time to time regularly monitored. The analysis 
of CP was performed by HPLC/MS/MS after lyophilisation and extraction with dichloromethane.   
 
RESULTS 
 
The experiments were performed during day 160in the first experimental campaign and day 223 in the 
second one. Day 21 was the first day addition of cyclophosphamide and its principal metabolites to MBR 
pilot during the first experimental campaign and day 108 during the second one. 
 
Cyclophosphamide removal efficiency in MBR 
 
To compare the performance of MBR pilot in both campaigns, Figure 2 illustrates the CP removal 
efficiencies. The axis of time is 
recalculated, the day 0 being 
the first day of the cocktail 
addition. After 70 days 
continuous addition of the 
cocktail (CP and its principal 
metabolites), the CP removal 
efficiencies is about 80% 
during the two campaigns 
(Figure 2). According to these 
results, it appears that a sludge 
age of 50 days is sufficient to 
achieve removals efficiency of 
80%. The increase in sludge 
age to 70 days does not 
improve significantly the 
removal efficiency. However, 
the question about the removal 
of CP at ages sludge less than 
50 days is still open.  
 
Cytotoxic removal efficiency in MBR 
 
The evaluation of cytotoxicity was achieved by measuring the proliferation of treated cells compared to 
control (untreated cells). Proliferation was measured quantitatively by the colorimetric tetrazolium (MTT) 
and based on the metabolic activity of viable cells. Tests of cell proliferation were made on human liver 
cells (HepG2) because this cell line was most sensitive to the effects of the products tested [14]. 
 
In order to establish a link between the cytotoxicity (death or proliferation) observed in the supernatant 
and permeate of MBR pilot and bioreactor behaviour, we recalculate the toxicity measured as the absolute 
values of difference between the values 
of viability (death or proliferation) for 
cytotoxicity tests compared to 100% 
viability of the control. These values, 
in the supernatant and in the permeate, 
are represented in Figure 3(a) and (b), 
respectively for the first campaign. The 
evolution of transmembrane pressure 
during the experimental campaign I is 
also presented. It is interesting to note 
that during the first experimental 
campaign, Figure 3a: the increase in 
cytotoxicity in supernatant MBR pilot 
occurred around the days when 
transmembrane pressure increased, 
days 64, 108 and 145. 
Figure 3b: for some days (63 and 116-
131), when the transmembrane 
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pressure decreased widely, the permeate 
toxicity increased significantly (drastic 
changes of the parameter in 
concomitant). 
 
Figure 4 shows supernatant and permeate 
MBR pilot cytotoxicity and the evolution 
of the humic acids and polysaccharides 
concentration in the time. Increased 
cytoxicity was observed in the 
supernatant and the permeate, on days 
when the concentration of humic acid 
also increased. Furthers research are 
needed to evaluate if this phenomena was 
due to the formation of new toxics 
cyclophosphamide metabolites. Anyway , 
these graphs strongly suggested that these 
toxic compounds are adsorbed on the 
colloidal particles and humic substances, which are themselves retained by the membrane.  
 
Discussion 
 
The issue concerning the presence 
and the potential risks associated with 
micropollutants in the environment 
has become a highlighted topic. 
Today, the wastewater treatment 
plants are not able to adequately 
remove this new type of pollution. 
Therefore, it is necessary to consider 
a more effective treatment to 
eliminate these compounds upstream 
sewage treatment plants. 
 
Preliminary investigations in a 
simplified test system indicated a low 
degradability of CP [3, 15].  Based 
on the degradation studies in 
laboratory scale sewage treatment 
plant and the analytical findings in 
sewage water, Steger-Hartmann et al, 
1997 concluded that excreted CP is 
only poorly degraded during its 
passage through the sewage treatment 
plant [6]. Even though other studies 
indicated, that CP is not or poorly 
biodegradable, we observed a 
removal of this molecule in our study. 
Removal of CP started from the 
beginning of experiment (fig. 2). At 
steady-state conditions, the 
pharmaceuticals removal efficiencies 
remained quite stable, up to 80% for 
CP, and proved the ability of the 
MBR for the cytotoxic compounds 
partial removal. In another previous 
study, it was documented that both 
adsorption and degradation affect the 
overall removal [16]. Furthermore, 
sorption may also influence the rate 
of other processes such as 
Figure 4. Supernatant (a) and permeate (b) MBR pilot cytotoxic 
and variation of humic acid and polysaccharides in the MBR 
during the experimental campaign I. 
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biodegradation [17]. As CP was present at low concentrations, CP could not be used as the primary source 
of energy/carbon, so it could be suggested that CP was cometabolically degraded. In previous studies, 
some authors indicate that cometabolic transformation may be the major removal mechanism of some 
PhAC compounds in activated sludge treatment of municipal wastewater [18, 19].  
 
In the same previous study [16], it was also demonstrated that CP and its metabolites toxicity do not alter 
COD and total nitrogen removal efficiency of MBRs. Removal rates observed for COD and TN were 
above 90% and 93% respectively. COD removal in the system was attributable to two factors, one was 
biological removal by 
micro-organisms and the 
other was physical retention 
by the membrane. Figure 5 
illustrates the important role 
of membrane filtration in the 
performance of MBR. After 
increasing the crossflow 
velocity, the supernatant 
COD content in MBR 
increased considerably 
nevertheless, the permeate 
COD concentration was 
almost constant after 
increasing the crossflow 
velocity on day 65. It points 
out the role of membrane in 
the quality of permeate.  
 
 
The evaluation of this technology (membrane bioreactors) in industrial scale on long-term hospital 
effluent, preferably at the exit of Oncology service, or on wastewater from the pharmaceutical industry 
will ultimately clarify the industrial-scale membrane bioreactor potential in the chemical removal of 
cytotoxic compounds and their associated toxicity. However, membrane bioreactors offer two important 
advantages for the elimination of pharmaceutical compounds from hospital wastewater: 
1. The compact design allows implementation at the hospital site. 
2. The possibility of operation at high sludge ages to adapt the biomass to the micropollutant. In these 
conditions the amount of sludge produced is reduced, and the simultaneous elimination of the COD and 
nitrogen can be conducted under operating conditions selected. In addition, if the sludge become toxic 
when treating hospital wastewater, treatment by incineration would become relevant. The decrease in the 
quantity of sludge to incinerate represents a reduction of operating costs. 
 
 
CONCLUSION 
 
The continuous release of Cytostatics via hospital wastewater is problematic. Cytostatics belong to the 
CMR (carcinogenic, mutagenic and reprotoxic) drugs. As hospital effluents reach the municipal sewage 
network generally without any preliminary treatment, their presence in the environment could affect 
animal and human health, but also the plants. In this work, MBR was operated in order to evaluate its 
potential for cytostatic drugs bioremoval. The alkylating antineoplastic drug Cyclophosphamide (CP) 
which is one of the oldest known cytostatics and is one of the most frequently used agents in cancer 
chemotherapy has been chosen. CP removal up to 80% was achieved under a hydraulic retention time of 
48h, a solid retention time of 50 days. Variation of sludge age between 50 and 70 days showed no 
significant impact on the transformation efficiency of CP. The results of this study proved that advances 
wastewater treatment using a MBR provides a suitable process for lowering CP concentrations before 
discharge into the aqueous environment. Despite of this clear benefit of MBR, the removal is only 
partially achieved and a tertiary treatment is necessary for the complete elimination of cytostatic 
compounds toxicity.  
 
Acknowledgements 
This study is supported by the National Research Agency (France) as a part of the project 
“TOXEAUBAM”.  
 
 
0
500
1000
1500
2000
2500
3000
3500
4000
4500
0 20 40 60 80 100 120 140 160
operation time (d)
CO
D
 
m
g/
l
influent COD MBR Supernatant COD MBR permeate COD MBR
First day: Addition of 
Cyclophosphamide and 
metabolites to MBR
Increasing crossflow 
velocity from 4 to 5 m/s 
(flow rate 700 L/h)
Change of 
membranes
Figure 5. COD concentration MBR influent, MBR supernatan and MBR 
permeate during the experimental campaign I. 
REFERENCES 
 
1. Larsen T.A., Lienert J., Joss A., Siegrist H. (2004). How to avoid pharmaceuticals in the aquatic 
environment. Journal of Biotechnology 113, 295-304.  
2. Kümmerer K. (2001). Drugs in the environment: emission of drugs, diagnostic aids and disinfectants 
into wastewater by hospitals in relation to other sources – e review. Chemosphere 45, 957-969. 
3. Buerge I. J., Buser H. R., Poiger T., Müller M. D.. Ocurrence and fate of the Cytostatic Drugs 
Cyclophosphamide and ifosfamide in Wastewater and surface Waters. Environ. Sci. Technol. 40, 
(2006),  7242-7250. 
4. Johnson Andrew C., Jürgens Monika D., Williams Richard J., Kümmerer Klaus, Kortenkamp 
Andreas,  Sumpter John P. (2008). Do cytotoxic chemotherapy drugs discharged into rivers pose a 
risk to the environment and human health? An overview and UK case study. Journal of Hydrology 
348, 167– 175 
5. Gilard V., Martino R., Malet-Martino M.C., Kutscher B., Müller A., Niemeyer U., Pohl J., 
Polymeropoulos E.E. (1994). Chemical and biochemical evaluation of hydrolysis products of 
cyclophosphamide. J. Med. Chem. 37, 3986-3993. 
6. Steger-Hartmann T., Kümmerer K., Hartmann A. (1997). Biological degradation of 
cyclophosphamide and its occurrence in sewage Water. Ecotoxicology and environmental safety. 36, 
174-179.  
7. Moore M.J. (1991) Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet 20, 1994-
208. 
8. Sladek N.E. (1994). Metabolism and pharmacokinetic behavior of cyclophosphamide and related 
oxazaphosphorines, in Anticancer Drugs: Reactive Metabolism and Drug Interactions (Powis G ed) 
pp 79–156, Pergamon Press, Oxford, UK. 
9. Joqueviel C., Martino R., Gilard V., Malet-Martino M., Canal P., Niemeyer U. (1998). Urinary 
excretion of cyclophosphamide in humnas, determined by phosphorus-31 nuclear magnetic resonante 
spectroscopy. Drug metabolism and Disposition.  26 (5), 418-428. 
10. Clara M., Kreuzinger N., Strenn B., Gans O., Kroiss H. (2005). The solids retention time –a suitable 
design parameter to evaluate the capacity of wastewater treatment plants to remove micropollutants. 
Water Res. 39, 97-106.  
11. De Wever H., Weiss S., Reemtsma T., Vereecken J., Müller J., Knepper T., Röden O., Gonzalez S., 
Barcelo D., Hernando M. D. (2007). Comparison of sulfonated and other micropollutants removal in 
membrane bioreactor and conventional wastewater treatment. Water research 41, 935-945.  
12. Frolund B., Griebe T., Nielsen O.H. (1995). Enzymatic activity in the activated sludge flocs matrix. 
Applied Microbiology and Biotechnology. 43, 755-761. 
13. Dreywood R.. Qualitative test for the carbohydrate material. Industrial Engineering Chemistry. 18, 
(1946), 499. 
14. Faucet-Marquis V, Delgado L, Dauta A, Albasi C and Pfohl-Leszkowicz A, Development of 
biomarkers for following decontamination of water after treatment of hospital water waste by 
membrane bioreactor process. One-day Meeting for UK Molecular Epidemiology Group in 
collaboration with ECNIS and NuGO held on 13 December 2007 at Pippard Lecture Theatre, 
Sherfield Building, South Kensington Campus, Imperial College, London, UK. Mutagenesis, July 
2008; 23: e1 - e4. 
15. Kümmerer K., Steger-Hartmann T., Baranyai A., Bürhaus I.  (1996). Prüfung des biologischen 
abbaus der Zytostatika Cyclophosphamid und ifosfamide mit dem closed bottle test (OECD 301 D). 
Zentralbl. Hyg. Umweltmed., 198, 215-225. 
16. Delgado, L.F., 2009. Bioréacteur à membrane externe pour le traitement d'effluents contenant des 
médicaments anticancéreux: élimination et influence du cyclophosphamide et de ses principaux 
métabolites sur le procédé. PhD thesis, INP Toulouse, France. http://ethesis.inp-
toulouse.fr/archive/00000816/ 
17. Bekbolet, M., Yenigun, O., Yucel, I. (1999). Sorption studies of 2,4-D on selected soils. Water Air 
Soil Pollut. 111 pages 75–88. 
18. De Wever H., Weiss S., Reemtsma T., Vereecken J., Müller J., Knepper T., Röden O., Gonzalez S., 
Barcelo D., Hernando M. D. (2007). Comparison of sulfonated and other micropollutants removal in 
membrane bioreactor and conventional wastewater treatment. Water research 41, 935-945.   
19. Joss A., Keller E., Alder A. C., Göbel A., McArdell C. S., Ternes T., Siegrist H. (2005). Removal of 
pharmaceuticals and fragrances in biological wastewater treatment. Water research 39 3139-3152.  
 
